Dimerix collaborates with UK's RaDaR for patient recruitment in Phase 3 trial

Dimerix Limited (ASX:DXB) has entered into a collaboration with the UK's National Registry of Rare Kidney Diseases (RaDaR) to enhance patient recruitment in the ACTION3 Phase 3 clinical trial. The collaboration aims to prospectively identify suitable FSGS patients for the trial, targeting a total of 286 patients globally. Recruitment is on-track with an interim analysis for the first 144 patients expected around mid-CY2025.

Executive Commentary on Collaboration and Trial Progress

We are very pleased to be working with RaDaR on this collaboration, as it represents a unique way to connect with FSGS patients across the United Kingdom for potential trial participation. The UK has an excellent renal research infrastructure, and RaDaR has a strong track record of assisting companies in bringing new treatments for rare renal diseases, such as FSGS, to recruit patients. - Dr David Fuller, Chief Medical Officer, Dimerix

Summary of Collaboration and Trial Progress

Dimerix's collaboration with the UK's National Registry of Rare Kidney Diseases (RaDaR) aims to enhance patient recruitment for the ACTION3 Phase 3 clinical trial, targeting 286 patients globally. The company has received approval for its Investigational New Drug Application (IND) from the Thai Food and Drug Administration (FDA) and expects clinical sites to initiate recruitment in Thailand in the coming weeks. The collaboration with RaDaR and the progress in obtaining regulatory approvals demonstrate Dimerix's commitment to advancing innovative therapies for rare kidney diseases like FSGS. The company's collaboration with RaDaR and the ongoing recruitment efforts reflect its dedication to addressing unmet medical needs in the field of kidney diseases.